JRP
DNLI icon

Jasper Ridge Partners’s Denali Therapeutics DNLI Stock Holding History

Jasper Ridge Partners’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-281,250
Closed -$5.81M – 89
2018
Q4 		$5.81M Hold
281,250
– – 0.36% 22
2018
Q3 		$6.11M Hold
281,250
– – 0.34% 21
2018
Q2 		$4.29M Buy
+281,250
New +$5.3M 0.34% 21

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Jasper Ridge Partners's DNLI Position: Q1 2019 in Review

Jasper Ridge Partners sold out of Denali Therapeutics (DNLI) in Q1 2019, closing a stake of 281,250 shares — an estimated $5.81M sold.

Jasper Ridge Partners first reported a position in DNLI in Q2 2018 and held it in 3 quarters. The position peaked at $6.11M in Q3 2018. 114 funds tracked by Wall St. Rank hold DNLI as of Q1 2019.

  • Jasper Ridge Partners reported no remaining Denali Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Jasper Ridge Partners sold 281,250 Denali Therapeutics shares in Q1 2019, an estimated $5.81M.
  • Jasper Ridge Partners first reported a position in Denali Therapeutics in Q2 2018 and held it in 3 quarters.
  • Jasper Ridge Partners's Denali Therapeutics position peaked at $6.11M in Q3 2018.
  • 114 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2019.

Based on Jasper Ridge Partners's 13F filing for Q1 2019, filed 13 May 2019.